Last reviewed · How we verify
Qassim Health Cluster — Portfolio Competitive Intelligence Brief
0 marketed
0 filed
1 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Mepivacaine 2% with epinephrine 1:100,000 | Mepivacaine 2% with epinephrine 1:100,000 | phase 3 | Local anesthetic | Voltage-gated sodium channels | Anesthesiology |
Therapeutic area mix
- Anesthesiology · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Ain Shams Maternity Hospital · 1 shared drug class
- Ain Shams University · 1 shared drug class
- Aligarh Muslim University · 1 shared drug class
- Atlantic Health System · 1 shared drug class
- Aultman Health Foundation · 1 shared drug class
- B.P. Koirala Institute of Health Sciences · 1 shared drug class
- Bagcilar Training and Research Hospital · 1 shared drug class
- Abant Izzet Baysal University · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Qassim Health Cluster:
- Qassim Health Cluster pipeline updates — RSS
- Qassim Health Cluster pipeline updates — Atom
- Qassim Health Cluster pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Qassim Health Cluster — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/qassim-health-cluster. Accessed 2026-05-17.